 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...107108109110111112113114115116117...858859» |
- ||| Prolia (denosumab) / Amgen, Daiichi Sankyo
Enrollment open, Trial completion date, Trial primary completion date: Efficacy and Safety of Actonel (clinicaltrials.gov) - Dec 11, 2023
P4, N=155, Recruiting, Sponsor: Dong-A ST Co., Ltd.
Not yet recruiting --> Recruiting | Trial completion date: Oct 2024 --> Feb 2025 | Trial primary completion date: Oct 2024 --> Feb 2025
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
From Error to Resolution: Utilizing a Multidisciplinary Team Approach to Improve Quality Outcomes () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1264;
Objective: At a mid-sized Midwest transplant center, a morbidity case was presented on regarding an error of missed filgrastim dosing x 10 days post haploidentical transplant... This process improvement project utilized a multidisciplinary team approach in the development of safety checkpoints to correct a complex high risk EMR release process.
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Hyperbaric Oxygen (HBO) Effects on Blood Count Recovery and Post-Transplant Outcomes Following High-Dose Therapy and Autologous HSPC Transplantation for Multiple Myeloma: An Updated Analysis of the Multicenter Phase II Randomized Clinical Trial () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_1250;
P1
Single HBO treatment did not impact 1- year progression-free survival. A pilot study (NCT04862676) is ongoing to determine if multiple HBO treatments can keep EPO levels low beyond Day +1 and impact outcomes.
- Tecartus (brexucabtagene autoleucel) / Gilead
Bridging Therapy in Adults with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Receiving Standard of Care Brexucabtagene Autoleucel: Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA) () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_926;
Survival was inferior in patients with pre-apheresis active disease who received bridging. In patients with < 5% blasts pre-apheresis, bridging did not impact survival.
- Nplate (romiplostim) / Amgen, Kyowa Kirin
Low-Dose Targeted Radioimmunotherapy (Iomab-ACT) Achieves Lymphocyte and Monocyte Depletion Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed of Refractory B-Cell ALL or DLBCL with Minimal CRS and Icans () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_876;
P1
Low-dose Iomab-ACT prior to 19-28z CAR-T depletes peripheral lymphocytes/monocytes and has minimal non-hematologic toxicity (including CRS/ICANS); cytopenias requiring blood product/growth factor support can occur in the weeks post-CAR-T. This pilot continues to enroll pts.
- Doptelet (avatrombopag) / SOBI
Avatrombopag Safe and Effective in Treatment of Severe Refractory Thrombocytopenia in a Pediatric Patient with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_847;
P3
Avatrombopag was well tolerated and provided a sustained response in a pediatric patient with refractory thrombocytopenia post haploidentical HSCT. Further data to be reported on this case, as well as the manufacturer Phase III trial will provide additional data for its use in the pediatric population (NCT04516967).
- Blincyto (blinatumomab) / Astellas, Amgen
Blinatumomab Therapy for Low Level Minimal Residual Disease Detected By Next-Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_774;
Further data to be reported on this case, as well as the manufacturer Phase III trial will provide additional data for its use in the pediatric population (NCT04516967). In B cell ALL, Blinatumomab may offer a CIR benefit to pts with low levels of MRD detected on clonoSEQ.
- Blincyto (blinatumomab) / Astellas, Amgen
Philadelphia-like B- Cell Acute Lymphoblastic Leukemia in a Largely Hispanic Population: Disease Features and Outcomes in the Era of Immunotherapy a Single Institutional Study () - Dec 11, 2023 - Abstract #TCTASTCTCIBMTR2024TCT_ASTCT_CIBMTR_771;
Ph-like B-Cell ALL represents a high-risk disease subtype of adult B-ALL, with poor EFS and frequent treatment failure. CRLF2 translocation confers worse CIR and EFS within Ph-like patients and requires novel treatment approaches.
- || Retrospective data, Review, Journal: Clinical effectiveness of pharmacological interventions for managing chronic migraine in adults: a systematic review and network meta-analysis. (Pubmed Central) - Dec 11, 2023
The absolute differences in the number of headache/migraine days are, at best, modest. No evidence was found to determine the relative effectiveness of the six included drugs with other oral preventive medications.
- | Journal: Hepatitis B vaccination associated with low response in patients with rheumatic diseases treated with biologics. (Pubmed Central) - Dec 11, 2023
HBV vaccination response in patients with rheumatic diseases treated with bDMARDs was poorer than expected. Our data reinforce the recommendation for vaccination prior to starting bDMARDs.
- || Praluent (alirocumab) / Sanofi, Regeneron, Leqvio (inclisiran) / Alnylam, Novartis, Repatha (evolocumab) / Amgen, Astellas
Retrospective data, Review, Journal: Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis. (Pubmed Central) - Dec 11, 2023
PCSK9 inhibitors (Evolocumab, Alirocumab) and siRNA therapy (Inclisiran) significantly reduced LDL-c by >40% in high-risk individuals. Additionally, both Alirocumab and Evolocumab reduced the risk of MACE, and Alirocumab reduced cardiovascular and all-cause mortality.
- | omecamtiv mecarbil (AMG 423) / Amgen, Servier
Journal: Sex Differences in Heart (Pubmed Central) - Dec 11, 2023
P3
The beneficial effect of omecamtiv mecarbil did not significantly differ by sex. (Registrational Study With Omecamtiv Mecarbil [AMG
- || Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Biomarker, Clinical, Observational data, Retrospective data, Review, Journal: Cutaneous Naganishia albida (Cryptococcus albidus) infection: a case report and literature review. (Pubmed Central) - Dec 11, 2023
Serum cryptococcal antigen was negative in six patients, and diagnosis was made by fungal culture in all. There is a lack of data on optimal antifungal treatment and outcomes.
- | cyclophosphamide / Generic mfg., epirubicin / Generic mfg., albumin-bound paclitaxel / Generic mfg.
Journal: Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer. (Pubmed Central) - Dec 11, 2023
There is a lack of data on optimal antifungal treatment and outcomes. Neoadjuvant dose-dense biweekly nanoparticle albumin-bound paclitaxel followed by dose-dense epirubicin and cyclophosphamide was effective, especially in patients with triple-negative disease, and feasible with pegfilgrastim support.
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Reimbursement, US reimbursement, Journal: Antiresorptive drugs and the risk of femoral shaft fracture in men and women with osteoporosis: A cohort study using the National Database of Health Insurance Claims of Japan. (Pubmed Central) - Dec 11, 2023
The incidence rates of femoral shaft fracture varied across patients treated with different antiresorptive drugs. Further research on a specific antiresorptive drug can increase understanding of the risk of femoral shaft fracture.
- | Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
New trial: START: Sequential Therapies After Osteoanabolic Treatment (clinicaltrials.gov) - Dec 11, 2023
P=N/A, N=150, Recruiting, Sponsor: 424 General Military Hospital
- | fludarabine IV / Generic mfg., thiotepa / Generic mfg.
Trial completion date, Trial primary completion date: Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation (clinicaltrials.gov) - Dec 11, 2023
P2, N=40, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Further research on a specific antiresorptive drug can increase understanding of the risk of femoral shaft fracture. Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Jun 2024
- | Orserdu (elacestrant) / Menarini
Phase classification: ELEVATE: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer (clinicaltrials.gov) - Dec 11, 2023
P1/2, N=322, Recruiting, Sponsor: Stemline Therapeutics, Inc.
Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Jun 2024 Phase classification: P1b/2 --> P1/2
- | vudalimab (XmAb717) / Xencor, Stivarga (regorafenib) / Bayer
Trial initiation date: Regorafenib and XmAb20717 in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy (RX-CROME) (clinicaltrials.gov) - Dec 10, 2023
P2, N=16, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
Phase classification: P1b/2 --> P1/2 Initiation date: Nov 2023 --> Nov 2024
- || Review, Journal: Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes. (Pubmed Central) - Dec 10, 2023
However, ranolazine, in addition to symptom relief properties, is an antianginal drug showing favorable effects in decreasing the arrhythmic burden and in ameliorating the glycemic profile of these patients. In this review, we summarize the available data regarding the antianginal and pleiotropic effects of this drug.
- ||| Journal, Adverse events: Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study). (Pubmed Central) - Dec 10, 2023
While JAKi overall were not associated with more treatment discontinuations for AEs, subgroup analyses suggest varying patterns with specific JAKi, such as tofacitinib, compared with TNFi. However, these observations should be interpreted cautiously, given the observational study design.
- | Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Journal: Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis. (Pubmed Central) - Dec 10, 2023
Interventions to optimise SDL may improve treatment response earlier. This study suggests 3-month SDL thresholds which may be useful in clinical practice to optimise treatment response.
- || Cyramza (ramucirumab) / Eli Lilly, Stivarga (regorafenib) / Bayer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Biomarker, Review, Journal, Tumor microenvironment: The Complexity of the Tumor Microenvironment in Hepatocellular Carcinoma and Emerging Therapeutic Developments. (Pubmed Central) - Dec 9, 2023
It highlights the potential of second-line treatments, such as regorafenib, cabozantinib, and ramucirumab, in improving overall survival for advanced HCC patients who have progressed on or were intolerant to first-line therapy...The BCLC system, which incorporates tumor stage, liver function, and performance status, provides a framework for treatment stratification and prognosis prediction in HCC patients. The insights gained from this review contribute to the development of novel therapeutic interventions and personalized treatment approaches for HCC patients, ultimately improving clinical outcomes in this challenging disease.
- || Matulane (procarbazine hydrochloride) / Leadiant Biosci
Review, Journal: Temozolomide, Procarbazine and Nitrosoureas in the Therapy of Malignant Gliomas: Update of Mechanisms, Drug Resistance and Therapeutic Implications. (Pubmed Central) - Dec 9, 2023
Recent studies have revealed that senescence is the main trait induced by TMZ in glioblastoma cells, exhibiting hereupon the senescence-associated secretory phenotype (SASP). Strategies to eradicate therapy-induced senescence by means of senolytics as well as attenuating SASP by senomorphics are receiving increasing attention, with therapeutic implications to be discussed.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Journal: Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal. (Pubmed Central) - Dec 9, 2023
In our study, the three anti-CGRP mAbs presented a similar response, with no significant differences, during the first year of therapy, the suspension period, and 3 months after the drug reprisal. The response rate during the 1-month suspension period in chronic migraineurs may be higher with galcanezumab.
- | Stivarga (regorafenib) / Bayer
Preclinical, Journal, Cytology: Effect of Intraperitoneal Chemotherapy with Regorafenib on IL-6 and TNF-? Levels and Peritoneal Cytology: Experimental Study in Rats with Colorectal Peritoneal Carcinomatosis. (Pubmed Central) - Dec 9, 2023
compared to groups A and C, but there was no significant difference between them. Both B and D groups presented a statistically significant difference regarding the rate of negative peritoneal cytology, when compared to the control group, but not to group C. In conclusion, regorafenib-based IPEC, combined with CRS, may constitute a promising tool against peritoneal carcinomatosis by altering the tumor microenvironment.
- || Krazati (adagrasib) / Mirati, Lumakras (sotorasib) / Amgen
Preclinical, Review, Journal, IO biomarker, Metastases: Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers. (Pubmed Central) - Dec 9, 2023
Though classically difficult to target, recently developed KRAS G12C inhibitors (sotorasib and adagrasib) have now overcome this therapeutic hurdle...Though these medications demonstrate substantial response rates in a heavily pre-treated advanced NSCLC cohort, as phase-3 evidence does not yet demonstrate an overall survival benefit versus standard-of-care chemotherapy, docetaxel...Despite this, it is undeniable that these medications represent an important advancement in targeted and personalised oncological treatment. Current and future trials assessing these medications in combination and through sequencing strategies will likely yield further clinically meaningful outcomes to guide treatment in this patient cohort.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: Bone marrow necrosis after treatment with blinatumomab for acute lymphoblastic leukemia: A case report. (Pubmed Central) - Dec 9, 2023
Current and future trials assessing these medications in combination and through sequencing strategies will likely yield further clinically meaningful outcomes to guide treatment in this patient cohort. No abstract available
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Preclinical, Journal: Granulocyte Colony-Stimulating Factor (Neupogen (Pubmed Central) - Dec 8, 2023
No abstract available Collectively, this work corroborates the results of a previous pilot large animal study, validates the utility of a rodent screening model, and provides further evidence for the potential clinical utility of Neupogen
- ||| Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
P3 data, Journal: Effect of Tezepelumab on the Humoral Immune Response to Seasonal Quadrivalent Influenza Vaccination in Patients with Moderate to Severe Asthma: The Phase (Pubmed Central) - Dec 8, 2023
P3b
There was no observed suppression of the humoral immune response after influenza vaccination in adolescents and young adults with moderate to severe asthma treated with tezepelumab. Therefore, the influenza vaccine can be administered to this patient population during tezepelumab treatment.
- | Repatha (evolocumab) / Amgen, Astellas
Journal, Real-world evidence, Real-world effectiveness, Real-world: Real-world effectiveness and safety of evolocumab in very high-risk atherosclerotic cardiovascular disease patients with acute ischemic stroke. (Pubmed Central) - Dec 8, 2023
Therefore, the influenza vaccine can be administered to this patient population during tezepelumab treatment. This real-world study suggested that evolocumab on a background of statin reduced the LDL-C levels significantly and lowered the incidence of recurrent cerebrovascular events in the very high-risk ASCVD patients with AIS in China.
- | Imdelltra (tarlatamab-dlle) / Amgen
Phase classification: DeLLphi-303: First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov) - Dec 8, 2023
P1, N=340, Recruiting, Sponsor: Amgen
This real-world study suggested that evolocumab on a background of statin reduced the LDL-C levels significantly and lowered the incidence of recurrent cerebrovascular events in the very high-risk ASCVD patients with AIS in China. Phase classification: P1b --> P1
- || briquilimab (JSP191) / Jasper Therap
New P1/2 trial: BEACON: Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU) (clinicaltrials.gov) - Dec 8, 2023
P1/2, N=44, Recruiting, Sponsor: Jasper Therapeutics, Inc.
- ||| botensilimab (AGEN1181) / Agenus, balstilimab (AGEN2034) / Agenus
Enrollment closed, Monotherapy: C-800-25: A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer (clinicaltrials.gov) - Dec 8, 2023
P2, N=230, Active, not recruiting, Sponsor: Agenus Inc.
Phase classification: P1b --> P1 Recruiting --> Active, not recruiting
- |||||||||| efruxifermin (AKR-001) / Akero Therap
New P3 trial: AK-US-001-0107: A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (clinicaltrials.gov) - Dec 8, 2023
P3, N=600, Recruiting, Sponsor: Akero Therapeutics, Inc
- | Prolia (denosumab) / Amgen, Daiichi Sankyo
Journal: Treatment for Gorham-Stout syndrome with a combination of teriparatide and denosumab. (Pubmed Central) - Dec 7, 2023
After treatment with bisphosphonates, this patient still had persistent resorption of the mandible, but switching to a teriparatide and denosumab combination yielded substantial improvement. This study is the first report to show that teriparatide combined with denosumab can be used to treat Gorham-Stout syndrome.
- | Journal, Gene Signature, IO biomarker: Identification of aneuploidy-related gene signature to predict survival in head and neck squamous cell carcinomas. (Pubmed Central) - Dec 7, 2023
This study is the first report to show that teriparatide combined with denosumab can be used to treat Gorham-Stout syndrome. We classified 3 molecular subtypes for HNSC patients and established an ARS prognostic model, which offered a prospective direction for prognosis in HNSC.
- | Vectibix (panitumumab) / Amgen, Takeda, Lumakras (sotorasib) / Amgen
Journal: Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. (Pubmed Central) - Dec 7, 2023
P3
Toxic effects were as expected for either agent alone and resulted in few discontinuations of treatment. (Funded by Amgen; CodeBreaK 300 ClinicalTrials.gov number, NCT05198934.).
- || Prolia (denosumab) / Amgen, Daiichi Sankyo, Crysvita (burosumab) / Ultragenyx, Kyowa Kirin, Voxzogo (vosoritide) / BioMarin
Review, Journal: NOVEL TREATMENT OPTIONS IN CHILDHOOD BONE DISEASES. (Pubmed Central) - Dec 7, 2023
Burosumab is more etiology-based and convenient in comparison to conventional treatment of X-linked hypophospha--temic rickets in children and adults. Vosoritide importantly changes the natural course of achondroplasia, at least in the short term.
- | ToleraCell / Diabetes Free, DFI-105 / Diabetes Free
New P1/2 trial: Tolerance to Islet Allotransplants in Diabetes (clinicaltrials.gov) - Dec 7, 2023
P1/2, N=12, Not yet recruiting, Sponsor: Diabetes Free, Inc.
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion date, Metastases: AlloHCT From Matched Unrelated Donors in Pts w/ Advanced Hematologic Malignancies & Disorders (clinicaltrials.gov) - Dec 7, 2023
P=N/A, N=10, Active, not recruiting, Sponsor: City of Hope Medical Center
Vosoritide importantly changes the natural course of achondroplasia, at least in the short term. Trial completion date: Sep 2023 --> Jun 2024
- | Ibrance (palbociclib) / Pfizer, Mektovi (binimetinib) / Pfizer
Enrollment open: Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial (clinicaltrials.gov) - Dec 7, 2023
P2, N=199, Recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Sep 2023 --> Jun 2024 Not yet recruiting --> Recruiting
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date, Metastases: PALATINE: Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients (clinicaltrials.gov) - Dec 7, 2023
P=N/A, N=200, Active, not recruiting, Sponsor: UNICANCER
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2023 --> Oct 2024
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 7, 2023
P3, N=488, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Oct 2023 --> Oct 2024 Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023
- daxdilimab (HZN-7734) / Amgen
Phase classification: HZNP-DAX-201: Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata (clinicaltrials.gov) - Dec 7, 2023
P2, N=30, Active, not recruiting, Sponsor: Horizon Therapeutics Ireland DAC
Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Jun 2023 Phase classification: P2a --> P2
- Health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC) treated with sotorasib and panitumumab (pmab) versus trifluridine/tipiracil (T/T) or regorafenib (rego) in CodeBreaK 300. () - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_866;
P3
In addition to improved clinical outcomes, these findings provide further evidence on the benefit of soto+pmab in patients with chemorefractory mCRC. Clinical trial information: NCT05198934.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
High-resolution transcriptional signature to predict survival benefit in colorectal cancer (CRC) treated with EGFR inhibitors (EGFRi) independent of RAS/BRAF mutation status or tumor sidedness. (Level 1, West Hall; Poster Bd # M11) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_846;
Patients with high CTX-S had increased prevalence of CMS2 and harbored more APC and TP53 mutations. A strong EGFRi biomarker would likely expand the utility of EGFRi to right-sided tumors and possibly to RASMUT tumors.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Impact of acquired RAS, BRAF and PIK3CA mutation at 8 weeks on the efficacy of anti-EGFR monoclonal antibodies in metastatic colorectal cancer. (Level 1, West Hall; Poster Bd # M1) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_837;
The association of ctDNA status with survival outcomes will be presented in 2025. Clinical trial information: jRCT1050210160.
- Stivarga (regorafenib) / Bayer
Preclinical analysis and clinical validation to identify biomarkers of regorafenib efficacy in patients with metastatic colorectal cancer. (Level 1, West Hall; Poster Bd # K19) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_815;
Clinical trial information: jRCT1050210160. Our preclinical data-based translational validation study suggests that MMP14 and MMP9 may serve as a prognostic marker of regorafenib, and the results also provide insight for novel combination therapy with anti-MMP9 agent or FTD/TPI.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Real-world evaluation of clinical outcomes and long-term survivors in patients with BRAF-V600E metastatic colorectal cancer. (Level 1, West Hall; Poster Bd # K14) - Dec 6, 2023 - Abstract #ASCOGI2024ASCO_GI_810;
In this study, we identified approximately 25% of patients who are long-term survivors (OS >2 years). This reflects the real-world heterogeneity of clinical outcomes for patients with BRAF-V600E mCRC who did not receive BRAF/EGFR targeted therapy.